The risk of cancer associated with a broad range of organ doses was estimated in an international study of women with cervical cancer. Among 150,000 patients reported to one of 19 population-based cancer registries or treated in any of 20 oncology clinics, 4188 women with second cancers and 6880 matched controls were selected for detailed study. Radiation doses for selected organs were reconstructed for each patient on the basis of her original radiotherapy records. Very high doses, on the order of several hundred gray, were found to increase the risk of cancers of the bladder [relative risk (RR) = 4.0], rectum (RR = 1.8), vagina (RR = 2.7), and possibly bone (RR = 1.3), uterine corpus (RR = 1.3), cecum (RR = 1.5), and non-Hodgkin's lymphoma (RR = 2.5). For all female genital cancers taken together, a sharp dose-response gradient was observed, reaching fivefold for doses more than 150 Gy. Several gray increased the risk of stomach cancer (RR = 2.1) and leukemia (RR = 2.0). Although cancer of the pancreas was elevated, there was no evidence of a dose-dependent risk. Cancer of the kidney was significantly increased among 15-year survivors. A nonsignificant twofold risk of radiogenic thyroid cancer was observed following an average dose of only 0.11 Gy. Breast cancer was not increased overall, despite an average dose of 0.31 Gy and 953 cases available for evaluation (RR = 0.9); there was, however, a weak suggestion of a dose response among women whose ovaries had been surgically removed. Doses greater than 6 Gy to the ovaries reduced breast cancer risk by 44%. A significant deficit of ovarian cancer was observed within 5 years of radiotherapy; in contrast, a dose response was suggested among 10-year survivors. Radiation was not found to increase the overall risk of cancers of the small intestine, colon, ovary, vulva, connective tissue, breast, Hodgkin's disease, multiple myeloma, or chronic lymphocytic leukemia. For most cancers associated with radiation, risks were highest among long-term survivors and appeared concentrated among women irradiated at relatively younger ages.

Although leukemia occurs in few patients with breast cancer, significantly elevated risks were linked to treatments with regional radiation and alkylating agents. Melphalan is a more potent leukemogen than cyclophosphamide or radiotherapy. Low risks were associated with the levels of cyclophosphamide in common use today. Systemic drug therapy combined with radiotherapy that delivers high doses to the marrow appears to enhance the risk of leukemia.

Gouuiori (4) in 1953 pointed out that the substrate uuaphutiiol AS chboro:ocetate gave entirely olifferemut histochuemuuio'al pictures of estertose activity itu tissuo's thuauu the regulttr naphuthol aoetates, anb with this substrate hue miO)t('(l strikimug staining reaotions in normal and leukemic iueutrophuihie leukocyto's. Recently * This ituVe-sIigtotio)tt us-its uipporteol IIy a research grtomut (AI-30-l) 1571 from the Atomic Euuergy Conunuuis-siolnu tomud NIH granul C.Y. 4724. t Part lv sumtlllolrtcoh hI\-I he Larkimu Futmid Resetorchi FelloIsss4hip prolvioteot by the Guild of St. Luikc, Bo&lomi, Mtoss ochsumsetti4. Prcsenitcd tot I hue Tcmil Is Autmiuttol meetimug of the Histochemictol Society,

The leukemia risk associated with partial-body radiotherapy for uterine corpus cancer was small; about 14 excess leukemia cases were due to radiation per 10,000 women followed for 10 years. Women aged 65 years or older had a radiation risk comparable with that found in younger women. The relationship of leukemia risk to radiation dose was found to be complex due to the competing processes of cell killing, transformation, and repair. At very high doses delivered at high rates, destruction of cells likely dominates, and the risk per unit dose is low. In the low dose range, where dose was protracted and delivered at relatively low dose rates, the leukemia risk appears lower than that projected from risk estimates derived from the instantaneous whole-body exposures of atomic bomb survivors.

Instances of central nervous system (CNS) lymphomatous involvement occurring amongst 592 cases of non-Hodgkin's lymphoma (NHL) seen between 1967 and 1977 were reviewed. Lymphomatous complications of the CNS were found in 52 patients (9%): 24 with meningeal lymphoma, 20 with epidural compression and 8 with intracerebral lymphoma. Intracerebral lymphoma presented clinically as large parenchymal deposits of tumor unrelated to leptomeningeal disease. Ninety-eight percent (50/52) of all patients had a diffuse histologic subtype and 82% (42/52) had either histiocytic or diffuse, poorly differentiated lymphocytic lymphoma. Bone marrow involvement was an additional determinant of risk and aided in the selection of patients for possible CNS prophylaxis. Either meningeal or intracerebral lymphoma developed in 35% (6/17) of patients with diffuse histiocytic lymphoma and positive bone marrow biopsies. This subgroup was particularly felt to warrant CNS prophylaxis. Further diagnostic and therapeutic management regarding CNS involvement in NHL is discussed.

Fifteen cases (3.1%) of localized myeloblastic tumors occurring among 478 patients with acute granulocytic leukemia (AGL) and chronic granulocytic leukemia (CGL) are described. The majority of tumors were discovered at autopsy. Numerous cases of chloroma associated with AGL have been reported; however, in this series, the incidence of myeloblastic tumors in CGL was twice as high. The importance of employing histochemical methods for myeloperoxidase activity to identify myeloblastic tumors is pointed out. Experience in this group of cases confirm the frequent involvement of the ovary and the common localization of myeloblastic tumors to perineural and epidural structures. With CNS involvement by myeloblastic tumors, pain and compression symptoms may be effectively relieved by laminectomy and local x-ray therapy. After the appearance of a myelogenous tumor in CGL, the course of the disease is rapidly progressive.

A new combination chemotherapy program (M-BACOD) was administered to 101 patients with advanced diffuse histiocytic and diffuse undifferentiated lymphoma (DHL and DUL). High dose methotrexate (M) 3 g/m2 with leucovorin factor rescue was given on day 14 between cycles of bleomycin (B), adriamycin (A), cyclophosphamide (C), oncovin (O), and dexamethasone (D) administered every 3 weeks for 10 cycles. The complete remission rate (CR) was 72% in all 101 patients or 77% in 95 evaluable patients. The median follow-up is 3 yr 2 mo with one-third of CR patients followed beyond 4 yr. Twenty-six percent of CR patients have relapsed with a projected 5-yr survival rate of 80% (5-yr disease-free rate 65%). The overall survival of all 101 study patients reaches a plateau at 59% projected out to 5 yr. Patients with prior therapy had a significantly lower CR rate than those without prior treatment (p = 0.001); however, no other unfavorable prognostic characteristics could be identified. Relapse in the central nervous system CNS occurred in only 5.4% of CR patients. M-BACOD results in prolonged survival and possible cure in a high proportion of all patients with DHL and DUL.

We have evaluated the relation between alkylating agents and leukemic disorders in 3363 1-year survivors of ovarian cancer who were treated in five randomized clinical trials and at two large medical centers. Overall, 28 patients developed acute nonlymphocytic leukemia (expected, 1.2) and 7 developed preleukemia. A 93-fold increased risk for acute nonlymphocytic leukemia was seen in 1794 women treated with chemotherapy; the incidence of leukemic disorders was 7.7/1000 women per year. Risk was highest 5 to 6 years after the first treatment and appeared to decrease thereafter. The use of radiation therapy did not affect risk. The 10-year cumulative risk (mean +/- SE) of acquiring a leukemic disorder was 8.5% +/- 1.6% after treatment with any alkylating agent, 11.2% +/- 2.6% after treatment with melphalan, and 5.4% +/- 3.2% after cyclophosphamide treatment. A dose-response relationship was apparent in 605 women receiving melphalan and suggested in 333 women receiving cyclophosphamide. Women receiving melphalan were two to three times as likely to develop leukemic disorders than were women receiving cyclophosphamide. These data indicate that choice of chemotherapeutic agent and drug dosage may influence significantly the risk for long-term adverse effects of cancer therapy.